Abstract
An open-label study evaluated the safety (n = 53) and pharmacokinetics (n = 8) of single-dose therapy with 1500 mg famciclovir (prodrug of penciclovir) for recurrent herpes labialis in adolescents. Mean Cmax, mean AUC0-, and clearance for penciclovir were 9.37 μg/mL, 31.8 μg • h/mL, and 38.2 L/h, respectively, and within the range extrapolated from data in adults. Adverse events were generally mild and transient.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 525-528 |
| Number of pages | 4 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 30 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2011 |
Funding
Supported by Novartis Pharmaceuticals Corporation.
Keywords
- adolescent
- famciclovir
- herpes labialis
- pharmacokinetics
- safety
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Pediatrics, Perinatology, and Child Health